Neoadjuvant relatlimab and nivolumab in resectable melanoma - Amaria, Rodabe N.; Postow, Michael; Burton, Elizabeth M.; Tetzlaff, Michael T.; Ross, Merrick I.; Torres-Cabala, Carlos; Glitza, Isabella C.; Duan, Fei; Milton, Denái R.; Busam, Klaus; Simpson, Lauren; McQuade, Jennifer L.; et al. (Nature (London), 2022)
Keywords: 631/67/1059/2325; 631/67/1813/1634; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Cancer therapies; Clinical trials; Drug Therapy, Combination; Humanities and Social Sciences; Humans; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; Immune system; Immunotherapy; Macrophages; Macrophages - drug effects; Melanoma; Melanoma - drug therapy; Melanoma - pathology; Melanoma - surgery; Metastases; Metastasis; Monoclonal antibodies; multidisciplinary; Myocarditis; Neoadjuvant Therapy - adverse effects; Neoadjuvant Therapy - methods; Neoplasm Staging; Nivolumab - adverse effects; Nivolumab - therapeutic use; Patients; Relativity; Response rates; Safety; Science; Science (multidisciplinary); Solid tumors; Surgery; Survival; Survival Rate; Targeted cancer therapy; Tumors